SELUTION SLR 014 PTCA Drug-Eluting Balloon
MedAlliance, LLC · Decision date Nov 6, 2026
What did the FDA approve?
The FDA recorded an approval decision on 2026-11-06 for P250041/S001, a PMA supplement to the SELUTION SLR™ 014 PTCA Drug-Eluting Balloon (product code OOB, cardiovascular; applicant MedAlliance, LLC). The supplement is listed as a Normal 180 Day Track No User Fee submission with reason Postapproval Study Protocol. This action covers the postapproval study protocol, not a new approval of the underlying device system.
The recorded statement describes the SELUTION4ISR Continued Follow-up Study, which will evaluate long-term safety and effectiveness of the SELUTION SLR PTCA DEB in 418 subjects from the premarket SELUTION4ISR study, with annual follow-up through 5 years post-procedure and efforts to minimize missing long-term data. The public documentation contains no documents, so the protocol details, endpoints and any conditions of approval cannot be verified here.
Whether the follow-up study has begun, its enrollment status and any FDA-required milestones are not stated in the available data and remain unknown.
FDA approval order statement
SELUTION4ISR Continued Follow-up Study will evaluate the long-term safety and effectiveness of the SELUTION SLR PTCA DEB in 418 subjects from the premarket study (SELUTION4ISR). Subjects will be followed annually through 5 years post-procedure, and all efforts will be made to minimize the amount of missing long-term data.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Cardiovascular
- Decision date
- Nov 6, 2026
- FDA change category
- Postapproval Study Protocol
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250041/S001
- Regulatory pathway
- PMA supplement
- Applicant
- MedAlliance, LLC
- Product code
- OOB
- Decision code
- APPR
- Decision date
- Nov 6, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Drug-eluting percutaneous transluminal coronary angioplasty catheter.
- Applicant
- MedAlliance, LLC
- Product code
- OOB
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250041. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250041 · Original PMA
SELUTION SLR 014 PTCA Drug-Eluting Balloon
P250041/S001 received
Application receipt date recorded by FDA.
P250041/S001 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P250041. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250041
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| MedAlliance, LLC | PMA approval | Sep 18, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
MedAlliance, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 4 Jenner, Suite 190, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P250041/S001
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records